2020
Chapter 11 Trials and tribulations: Clinical trials and the future
Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.Peer-Reviewed Original ResearchClinical trialsNeck cancerRecent landmark trialsRole of immunotherapyRisk stratification toolPromising clinical trialsMetastatic headPoor accrualSystemic treatmentLandmark trialsNeck specialistsStratification toolDedicated headTrialsCurrent standardCancerExciting advancesLack of fundingHeadImmunotherapyHPVHNSCCTherapyDiseasePathobiology
2019
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
Harrington K, Cohen E, Soulieres D, Dinis J, Licitra L, Ahn M, Soria A, Machiels J, Mach N, Mehra R, Burtness B, Lin J, Cheng J, Swaby R, Le Tourneau C. Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state. Journal Of Clinical Oncology 2019, 37: 6026-6026. DOI: 10.1200/jco.2019.37.15_suppl.6026.Peer-Reviewed Original ResearchPrior radiation treatmentSurvival benefitRadiation treatmentM diseaseEnd pointNeck squamous cell carcinomaDisease statesPrimary end pointSecondary end pointsPlatinum-based therapySquamous cell carcinomaITT populationCare chemotherapyMetastatic HNSCCRecurrent headCell carcinomaPembroInvestigator's choicePatientsDiseaseDefinitive conclusionsMetastaticPFSRecurrentTreatment
2018
P53 in Head and Neck Squamous Cell Carcinoma
Parameswaran J, Burtness B. P53 in Head and Neck Squamous Cell Carcinoma. Current Cancer Research 2018, 249-274. DOI: 10.1007/978-3-319-78762-6_9.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaCell carcinomaMore effective treatment strategiesTreatment of headEffective treatment strategiesAdvanced diseasePoor prognosisNeck cancerTreatment strategiesPatientsP53 pathwayCarcinomaPrognosisFunction mutationsP53TP53Intracellular roleHeadPathogenesisIllnessCancerMutationsDiseaseAdjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseLate-stage diseaseAdjuvant treatmentSalivary gland cancerAdverse featuresAdjuvant radiotherapyImproved survivalGland cancerMajor salivary gland cancerAddition of chemotherapyNational Cancer DatabaseAdjuvant therapySurvival benefitRetrospective studyCancer DatabaseImproved outcomesCancer casesPatientsChemotherapyDiseaseTreatmentRadiotherapySurvivalCancerTherapy
2014
New directions in perioperative management of locally advanced esophagogastric cancer.
Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book 2014, e172-8. PMID: 24857100, DOI: 10.14694/edbook_am.2014.34.e172.Peer-Reviewed Original ResearchOverview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2014, 1-5. DOI: 10.1007/978-1-4614-8815-6_1.Peer-Reviewed Original ResearchSquamous cell cancerSquamous cell carcinomaHigh recurrence ratePathobiology of headPotential therapeutic targetEarly-stage cancerMultimodality therapyCell cancerRecurrence rateCell carcinomaNeck cancerDevastating cancerMetastatic cancerStage cancerDifficult diseaseTherapeutic targetSubglottic larynxCancerProtein expression changesDiseaseNeckExpression changesImproved managementHeadSCCHN
2012
Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neck 2012, 35: 160-164. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionCarcinoma, Squamous CellDatabases, FactualFemaleFunctional LateralityHead and Neck NeoplasmsHumansIncidenceLymph NodesMaleNeoplasm InvasivenessNeoplasm StagingPapillomavirus InfectionsRetrospective StudiesRisk AssessmentSEER ProgramSex DistributionSurvival AnalysisTonsillar NeoplasmsUnited StatesConceptsBilateral neck diseaseHuman papillomavirus eraPrimary tonsillar cancerTonsillar cancerNeck diseaseAdvanced neck diseaseEnd Results ProgramNational Cancer InstituteCancer incidence dataIpsilateral diseaseAnnual incidenceResults ProgramRegional spread patternsBiologic behaviorCancer InstituteCancerDiseaseIncidence dataIncidenceSpread patternTherapyEpidemiology
2008
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck.
Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clinical Advances In Hematology And Oncology 2008, 6: 742-50. PMID: 18997665, PMCID: PMC2745918.Peer-Reviewed Original ResearchConceptsRecurrent/metastatic diseaseRole of cetuximabSquamous cell carcinomaTreatment of HNSCCEpidermal growth factor receptorMetastatic diseaseCell carcinomaFirst-line regimenStandard of careGrowth factor receptorSurvival benefitSignificant morbidityCurable diseaseClinical trialsSingle agentDrug AdministrationCetuximabEGFR inhibitorsHNSCCBeneficial effectsDiseaseMonoclonal antibodiesFactor receptorCarcinomaFollowing review
2007
Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer. Oncology 2007, 21: 964-70; discussion 970, 974, 976-7. PMID: 17715697.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorColorectal cancerGrowth factor receptorChemotherapy-refractory colorectal cancerMonoclonal antibodiesFront-line therapyUse of cetuximabFactor receptorPredictors of responseClinical useCancerPromising novelPanitumumabSuch agentsTherapyAntibodiesReceptorsCetuximabAgentsDisease
2002
Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies
Murren JR, Pizzorno G, DiStasio SA, McKeon A, Peccerillo K, Gollerkari A, McMurray W, Burtness BA, Rutherford T, Li X, Ho PT, Sartorelli A. Phase I Study of Perillyl Alcohol in Patients with Refractory Malignancies. Cancer Biology & Therapy 2002, 1: 130-135. PMID: 12170772, DOI: 10.4161/cbt.57.Peer-Reviewed Original ResearchConceptsPeak plasma concentrationPlasma concentrationsChronic basisDihydroperillic acidMean peak plasma concentrationLow-grade nauseaPerillyl alcoholStabilization of diseaseGastrointestinal side effectsH post ingestionPerillic acidMonoterpene perillyl alcoholStarting doseRefractory malignanciesPost ingestionSide effectsPatientsMajor metabolitePharmacokinetic studyDoseMicroMNauseaMalignancyAverage numberDisease